175 / 1068
US - Rectal Cancer Consortium
(randomized phase II)
MRI-defined T2-3 N0 or T
any
N1,2
RT 50.4 Gy +
5-FU/Cape
FOLFOX/CapeOX
16-18 weeks
R
E
S
T
Nonoperative
Management
(NOM)
for cCR
Primary endpoint: 3-year DFS
R
RT 50.4 Gy +
5-FU/Cape
FOLFOX/CapeOX
16-18 weeks
A
G
I
N
G
TME
for no cCR